When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Última revisão: 16 Mar 2025
Última atualização: 18 Sep 2023

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • baixo crescimento
  • baixa estatura
  • desenvolvimento puberal tardio/ausente
  • amenorreia primária
  • defeitos cardíacos congênitos
  • anormalidades esqueléticas
  • pescoço alado
  • linfedema periférico

Outros fatores diagnósticos

  • características dismórficas
  • amenorreia secundária
  • nevos melanocíticos múltiplos
  • otite média recorrente/grave
  • sopro e/ou clique sistólico de ejeção
  • habilidades sociais deficientes
  • anomalias oculares
  • hipertensão em membros superiores
  • unhas distróficas e/ou hiperconvexas

Fatores de risco

  • não há fatores de risco conhecidos

Investigações diagnósticas

Investigações a serem consideradas

  • exame de audiologia
  • exame oftalmológico
  • idade óssea
  • ecocardiograma
  • ressonância nuclear magnética (RNM) cardíaca
  • Hormônio folículo-estimulante e hormônio antimülleriano séricos
  • radiografia do esqueleto
  • ultrassonografia pélvica
  • ultrassonografia renal
  • testes da função tireoidiana
  • anticorpos antitireoide
  • TFHs/gama-glutamiltransferase/fosfatase alcalina
  • glicemia de jejum e hemoglobina glicada (HbA1c)
  • lipídios séricos
  • Nível de imunoglobulina A (IgA) e IgA antitransglutaminase tecidual
  • níveis de vitamina D

Algoritmo de tratamento

Colaboradores

Autores

Patricia Y. Fechner, MD

Medical Director

Differences of Sex Development Program

Medical Director Congenital Adrenal Hyperplasia (CAH) Center of Excellence

Medical Co-Director Turner Syndrome Clinic

Seattle Children’s Hospital

Professor of Pediatrics

University of Washington

Seattle

WA

Declarações

PYF is currently considering research using growth hormone in Turner syndrome sponsored by industry but no contract has been signed. She has been invited to participate in the 2023 updated Guidelines for Turner Syndrome in June 2023. She has also conducted contract research from Neurocrine BioSciences, Pfizer, Spruce Biosciences, and Ascendis Pharma. PYF has stock in Abbott Laboratories and AbbVie. She declares that these activities do not relate to the topic. PYF participated in Meet the Professor for the Endocrine Society 2019 Annual Meeting and is an author of references cited in this topic.

Agradecimentos

Dr Patricia Y. Fechner would like to gratefully acknowledge Dr Carolyn A. Bondy, a previous contributor to this topic.

Declarações

CAB is an author of references cited in this topic.

Revisores

Gerard Conway, MD

Consultant Endocrinologist

University College London Hospitals

London

UK

Declarações

GC declares that he has no competing interests.

Peter Hindmarsh, MD

Professor

Developmental Endocrinology Research Unit

Institute of Child Health

London

UK

Declarações

PH declares that he has no competing interests.

Vaneeta Bamba, MD

Associate Professor of Pediatrics

Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania

Philadelphia

PA

Declarações

VB declares that in Nov 2020, she was part of a Genetic Short Stature Advisory Board sponsored by NovoNordisk. VB is a member of the Turner Syndrome Society Scientific Advisory Board- this is not compensated. VB has no known upcoming financial interests or relationships.

O uso deste conteúdo está sujeito ao nosso aviso legal